NCT00290732: Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer |
|
|
| Completed | 1 | 20 | US | Intraductal arm, Doxorubicin HCl Liposome Injection, Dox-SL, Doxil TM, Intravenous arm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | Breast Cancer | 05/11 | 10/11 | | |
NCT00316875: Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer |
|
|
| Completed | 1 | 23 | US | lapatinib ditosylate, Doxil, Doxorubicin HCL Liposome Injection, Dox-SL | Northwestern University, National Cancer Institute (NCI) | Breast Cancer | 08/11 | 08/11 | | |
NCT01815294: A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer |
|
|
| Completed | 1 | 54 | US, Europe | DOXIL/CAELYX (doxorubicin) Treatment Sequence AB, DOXIL/CAELYX (doxorubicin) Treatment Sequence BA | Janssen Research & Development, LLC | Neoplasms, Neoplasms, Ovarian, Neoplasms, Breast, Advanced or Refractory Solid Malignancies | 12/14 | 12/14 | | |
NCT01333423: Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC) |
|
|
| Withdrawn | 1 | 0 | US | Liposomal Doxorubicin, Doxil, Doxorubicin Hydrochloride (Liposomal), Seliciclib | M.D. Anderson Cancer Center, National Institutes of Health (NIH) | Breast Cancer | 09/15 | | | |
NCT02131506: A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer |
|
|
| Terminated | 1 | 11 | Europe | Lapatinib, Caelyx, Lapatinib, Caelyx | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | HER-2 Positive Breast Cancer, Malignant Neoplasm of Breast | 01/16 | 01/16 | | |
NCT01145430: Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer |
|
|
| Completed | 1 | 45 | US | Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, DOX-SL, Doxil, Doxilen, Doxorubicin HCl Liposome, doxorubicin hydrochloride liposome, Duomeisu, Evacet, LipoDox, Liposomal Adriamycin, liposomal doxorubicin hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Pharmacological Study, Veliparib, ABT-888, PARP-1 inhibitor ABT-888 | National Cancer Institute (NCI) | Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma | 05/17 | | | |
